Overview

• The Drugs Controller General of India cleared Biocon’s Liraglutide drug substance alongside Biocon Pharma’s 6 mg/ml pre-filled pen and cartridge product.
• The approval covers the generic version of Victoza for treating insufficiently controlled Type 2 diabetes in adults, adolescents and children aged 10 and above.
• Chief Executive Siddharth Mittal called the nod a major step toward expanding patient access to GLP-1 therapy in India.
• India’s diabetes population exceeds 77 million and continues to grow, highlighting urgent demand for affordable treatments.
• Following the approval announcement, Biocon shares climbed 0.81 percent to Rs 336.75 on the BSE.